SynthesisRheumatology (Oxford, England)2025
The state of data sharing in rheumatology: a systematic review of top journal practices.
Synthesis in Rheumatology (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveTo evaluate data sharing statement (DSS) inclusion within rheumatology clinical studies published over the past 4 years in 10 top rheumatology journals.
methodsA systematic review was conducted of rheumatology clinical studies published in 10 leading journals between 1 January 2020 and 31 December 2023. Articles were included if they provided new primary data through original research and excluded if no new primary data were found. Key analyses included descriptive statistics and adjusted logistic regression to examine factors influencing DSS inclusion. The association between study designs was derived from this regression analysis.
resultsAfter 46 exclusions, 1108 of 1154 publications met inclusion criteria for analysis. Rheumatology was the most represented journal (285; 25.72%) and clinical trials the most common study design (591; 53.34%). Cohort studies were significantly less likely to include a DSS than clinical trials (adjusted odds ratio: 0.55; 95% CI: 0.37, 0.82; P = 0.004). Overall, 622 articles (56.13%) had a DSS. Six of the eight journals showed an overall increase in DSS inclusion from 2020 to 2023, with Rheumatology reaching 100% in 2023. Theme analysis of the 622 DSSs described most data as conditionally available (552; 88.75%) or requiring a data request (479; 77.01%).
conclusionOur study describes data sharing practices in rheumatology research, highlighting trends in DSS inclusion and journal policies' influence on them. While organizations like the American College of Rheumatology and National Institutes of Health have promoted these practices, inconsistencies remain. We recommend implementing a standardized DSS requirement during author submission to enhance transparency in rheumatology research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.